Kalina Michael, Tinkoff Glen, Gbadebo Adebayo, Veneri Paula, Fulda Gerard
Department of Surgery, Section of Trauma Services, Christiana Care Hospital and Health Center, Newark, Delaware 19718, USA.
Am Surg. 2008 Sep;74(9):858-61.
Trauma patients on prescribed warfarin therapy sustaining intracranial hemorrhage can be difficult to manage. Rapid normalization of coagulopathy is imperative to operative intervention and may affect outcomes. To identify and expedite warfarin reversal, we designed a protocol to administer a prothrombin complex concentrate. A Proplex T protocol was instituted in May 2004. It dictated that trauma patients with an International Normalized Ratio (INR) greater than 1.5, history of prescribed warfarin therapy, and intracranial hemorrhage on CT scan receive a prothrombin complex concentrate for reversal of their coagulopathy. Neither the protocol nor the factor concentrate was validated for use in this subset of trauma patients; therefore, adherence to the protocol and use of the factor concentrate was not mandatory. Patients not administered the prothrombin complex concentrate received vitamin K and fresh-frozen plasma. The protocol resulted in an increased number of patients receiving Proplex T (54.3% vs 35.4%, P = 0.047). Protocol patients had improved times to normalization of INR (331.3 vs 737.8 minutes, P = 0.048), number of patients with reversal of coagulopathy (73.2% vs 50.9%, P = 0.026), and time to operative intervention (222.6 vs 351.3 minutes, P = 0.045) compared with control subjects. There were no differences in intensive care unit (ICU) days, hospital days, or mortality. The Proplex T protocol increased the number of patients who received prothrombin complex concentrate, provided rapid normalization of INR, and improved time to operative intervention.
接受华法林治疗的创伤患者发生颅内出血时可能难以处理。迅速纠正凝血功能障碍对于手术干预至关重要,且可能影响治疗结果。为了识别并加速华法林的逆转,我们设计了一项应用凝血酶原复合物浓缩剂的方案。2004年5月制定了普乐可复T方案。该方案规定,国际标准化比值(INR)大于1.5、有华法林治疗史且CT扫描显示颅内出血的创伤患者应接受凝血酶原复合物浓缩剂以纠正凝血功能障碍。该方案和因子浓缩剂均未在这一创伤患者亚组中得到验证;因此,遵循该方案和使用因子浓缩剂并非强制性的。未接受凝血酶原复合物浓缩剂的患者接受了维生素K和新鲜冰冻血浆。该方案使接受普乐可复T的患者数量增加(54.3%对35.4%,P = 0.047)。与对照组相比,按照方案治疗的患者INR恢复正常的时间缩短(331.3分钟对737.8分钟,P = 0.048),凝血功能障碍逆转的患者数量增加(73.2%对50.9%,P = 0.026),手术干预时间缩短(222.6分钟对351.3分钟,P = 0.045)。在重症监护病房(ICU)住院天数、住院总天数或死亡率方面没有差异。普乐可复T方案增加了接受凝血酶原复合物浓缩剂的患者数量,使INR迅速恢复正常,并缩短了手术干预时间。